SMPD1 and hepatocellular carcinoma: In this context, both in vitro and in vivo data have shown so far that a lack of ASM or its pharmacological inhibition protects cells against hepatotoxic effects [15], while the addition of recombinant ASM augmented the antiproliferative effects of sorafenib treatment in a HCC mouse model [19].